Eton Pharmaceuticals, Inc. ETON
Set alert
52.18 USD -1.49 -2.78%
At close · Oct 30
53.94 +1.76 +3.38%
After hours · Oct 30, 5:36 PM ET
51.89 Day range 53.62
14.35 52-week range 64.43
- YTD
- +208.57%
- 1 year
- +185.92%
- Open
- 53.33
- Prev close
- 53.67
- Mkt cap
- 1.49B
- Vol
- 336.11K
- Avg vol
- 565.28K
- EPS
- 0.40
- P/E
- 130.45
- Div yield
- 0.00%
More statistics
- Low
- 51.89
- High
- 53.62
- Forward P/E
- 20.47
- Beta
- 0.90
- Short ratio
- 3.18
- Inst. own
- 71.64%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 56.16
- 200-d avg
- 35.52
- 1y target
- 71.50
2Y chart
Events in this range
- Aug 7, 2025Earnings: -0.1; estimate -0.01; surprise -900%
- Nov 6, 2025Earnings: -0.07; estimate 0.16; surprise -143.75%
- Mar 19, 2026Earnings: 0.05; estimate 0.12; surprise -58.33%
- May 14, 2026Earnings: 0.05; estimate 0.1; surprise -50%
- Jul 28, 2026Rating: Craig-Hallum · Buy → Buy
- Aug 11, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Aug 13, 2026Earnings: 0.35; estimate 0.1898; surprise 84.4%
- Aug 14, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Aug 14, 2026Rating: B. Riley Securities · Buy → Buy
- Aug 14, 2026Rating: Canaccord Genuity · Buy → Buy
- Oct 14, 2026Rating: HC Wainwright & Co. · Buy → Buy
Signals (86)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 29, 2026 | 3 days ago |
| SMA: Bearish | Oct 6, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Sep 30, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 14, 2026 | 2 months ago |
| RSI: Overbought | Aug 14, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 6, 2026 | 2 months ago |
| RSI: Overbought | Jul 28, 2026 | 3 months ago |
| RSI: Overbought | Jul 21, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 17, 2026 | 3 months ago |
| RSI: Overbought | Jul 17, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 16, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 15, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 14, 2026 | 3 months ago |
| RSI: Overbought | Jun 26, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 15, 2026 | 4 months ago |
| MACD: Sell Signal | May 27, 2026 | 5 months ago |
| RSI: Overbought | May 18, 2026 | 5 months ago |
| MACD: Buy Signal | May 4, 2026 | 6 months ago |
| RSI: Overbought | May 4, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 16, 2026 | 6 months ago |
| RSI: Overbought | Apr 14, 2026 | 6 months ago |
| RSI: Overbought | Mar 31, 2026 | 7 months ago |
| RSI: Overbought | Mar 19, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 12, 2026 | 7 months ago |
| SMA: Bullish | Mar 10, 2026 | 7 months ago |
| SMA: Bearish | Mar 9, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 5, 2026 | 8 months ago |
| RSI: Overbought | Feb 23, 2026 | 8 months ago |
| RSI: Overbought | Feb 19, 2026 | 8 months ago |
| SMA: Bullish | Feb 11, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 10, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 5, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 2, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 9, 2026 | 9 months ago |
| SMA: Bullish | Jan 5, 2026 | 10 months ago |
| SMA: Bearish | Jan 2, 2026 | 10 months ago |
| SMA: Bullish | Dec 22, 2025 | 10 months ago |
| SMA: Bearish | Dec 15, 2025 | 10 months ago |
| SMA: Bullish | Dec 11, 2025 | 10 months ago |
| SMA: Bearish | Dec 5, 2025 | 11 months ago |
| MACD: Buy Signal | Dec 4, 2025 | 11 months ago |
| SMA: Bullish | Dec 3, 2025 | 11 months ago |
| SMA: Bearish | Nov 24, 2025 | 11 months ago |
| SMA: Bullish | Nov 21, 2025 | 11 months ago |
| SMA: Bearish | Nov 20, 2025 | 11 months ago |
| SMA: Bearish | Nov 7, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 7, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 6, 2025 | 12 months ago |
| SMA: Bullish | Nov 5, 2025 | 12 months ago |
| SMA: Bearish | Oct 24, 2025 | 1 year ago |
| SMA: Bullish | Oct 21, 2025 | 1 year ago |
| SMA: Bearish | Oct 17, 2025 | 1 year ago |
| SMA: Bullish | Oct 14, 2025 | 1 year ago |
| SMA: Bearish | Oct 13, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 9, 2025 | 1 year ago |
| RSI: Overbought | Sep 23, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 19, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 10, 2025 | 1 year ago |
| SMA: Bullish | Aug 6, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 5, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 1, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 1, 2025 | 1 year ago |
| RSI: Oversold | Jun 12, 2025 | 1 year ago |
| SMA: Bearish | Jun 9, 2025 | 1 year ago |
| MACD: Sell Signal | May 29, 2025 | 1 year ago |
| RSI: Overbought | May 19, 2025 | 1 year ago |
| RSI: Overbought | May 15, 2025 | 1 year ago |
| RSI: Overbought | Apr 30, 2025 | 1 year ago |
| SMA: Bullish | Apr 22, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 14, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 25, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 24, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 21, 2025 | 1 year ago |
| SMA: Bearish | Mar 17, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 17, 2025 | 1 year ago |
| SMA: Bullish | Mar 14, 2025 | 1 year ago |
| SMA: Bearish | Mar 6, 2025 | 1 year ago |
| SMA: Bullish | Feb 26, 2025 | 1 year ago |
| SMA: Bearish | Feb 20, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 10, 2025 | 1 year ago |
| RSI: Overbought | Jan 31, 2025 | 1 year ago |
| RSI: Overbought | Jan 28, 2025 | 1 year ago |
| RSI: Overbought | Jan 24, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 15, 2025 | 1 year ago |
Key statistics
- Market cap
- 1.49B
- Enterprise value
- 1.54B
- Trailing P/E
- 130.49
- Forward P/E
- 20.47
- PEG ratio
- 0.00
- Price / sales
- 14.13
- Price / book
- 31.69
- EPS (TTM)
- 0.40
- Beta
- 0.90
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 12.02%
- Revenue (TTM)
- 105.59M
- Revenue growth
- 98.60%
- Free cash flow
- 6.58M
- Total cash
- 26.84M
- Total debt
- 29.23M
- Return on equity
- 35.97%
- Shares outstanding
- 28.58M
- Short % of float
- 9.40%
- 50-day average
- 56.16
- 200-day average
- 35.52
Analyst view
Consensus: none
Price target (mean) 71.50 +37.0% upside
Now 52.18
- Target (low)
- 68.00
- Target (mean)
- 71.50
- Target (high)
- 78.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy0
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 0.37.
Financials — quick view
ETON Revenue — quarterly 37.59M
ETON Net income — quarterly 11.58M
ETON EPS — quarterly 0.42
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | 0.3125 | — | — | — |
| Aug 13, 2026 | Jun 30, 2026 | 0.1898 | 0.35 | +0.16 | +84.40% |
| May 14, 2026 | Mar 31, 2026 | 0.10 | 0.05 | -0.05 | -50.00% |
| Mar 19, 2026 | Dec 31, 2025 | 0.12 | 0.05 | -0.07 | -58.33% |
| Nov 6, 2025 | Sep 30, 2025 | 0.16 | -0.07 | -0.23 | -143.75% |
| Aug 7, 2025 | Jun 30, 2025 | -0.01 | -0.10 | -0.09 | -900.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 14, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 14, 2026 | Canaccord Genuity | main | Buy | Buy |
| Aug 14, 2026 | B. Riley Securities | reit | Buy | Buy |
| Aug 14, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 11, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 28, 2026 | Craig-Hallum | main | Buy | Buy |
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- etonpharma.com
News
- Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
- Eton Pharmaceuticals, Inc. $ETON Shares Newly Bought by Robeco Institutional Asset Management B.V.
- Eton Pharmaceuticals Lands Exclusive US Rights To Aquestive's Seizure Rescue Drug
- HC Wainwright & Co. Reiterates Buy on Eton Pharmaceuticals, Maintains $70 Price Target
- Eton Pharmaceuticals And Aquestive Therapeutics Enter Exclusive U.S. License And Supply Agreement For LIBERVANT Buccal Film For Seizure Clusters In Patients With Epilepsy; Sees Commercial Availability In April 2027
- Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
- Financial Survey: Eton Pharmaceuticals (NASDAQ:ETON) vs. Cronos Group (NASDAQ:CRON)
- ETON Stock Surges 108% in Six Months: Here's What You Need to Know
- Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules
- Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Has Consensus Price Target of $67.50 According to Brokerages
Your note
Sign in to keep a note on ETON — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAMS JENNIFER MCKIE | Director | Sale | Jun 16, 2026 | 0 |
| BRYNJELSEN SEAN E | Chief Executive Officer | Sale | Aug 19, 2026 | 961,194 |
| GRUBER JAMES R | Chief Financial Officer | Sale | Aug 19, 2025 | 204,753 |
| KREMPA DAVID | Officer | Sale | Oct 5, 2026 | 43,381 |
| MAIER PAUL V | Director | Sale | Aug 27, 2026 | 59,745 |
| OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | Jul 13, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Opaleye Management Inc. | 10.01% | 2,860,000 | 149.28M | Jun 29, 2026 |
| EcoR1 Capital, LLC | 7.60% | 2,171,938 | 113.36M | Jun 29, 2026 |
| Blackrock Inc. | 6.63% | 1,895,833 | 98.95M | Jun 29, 2026 |
| Nantahala Capital Management, LLC | 4.11% | 1,175,951 | 61.38M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.42% | 976,570 | 50.97M | Jun 29, 2026 |
| Morgan Stanley | 2.69% | 767,972 | 40.08M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Russell 2000 ETF | 2.42% | 690,942 | 36.06M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.40% | 684,821 | 35.74M | Jun 29, 2026 |
| OBERWEIS FUNDS-Oberweis Micro-Cap Fund | 1.69% | 483,900 | 25.26M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.02% | 291,898 | 15.24M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.95% | 271,079 | 14.15M | Jun 29, 2026 |
| TIAA-CREF Funds-Nuveen Quant Small Cap Equity Fund | 0.89% | 253,380 | 13.23M | Jul 30, 2026 |